Open Orphan, Vadim Alexandre on Covid19 Stocks and John Meyer on Resource Stocks
Justin Waite
Vox Markets Podcast with Justin Waite
12:03, 24th June 2020

AudioBoom Player

DYOR Disclaimer

If you find this podcast useful please give it a rating and review on iTunes by clicking here

Do you want to get instant company alerts to the front screen of your smartphone? Download the Vox Markets app here:

On today's Vox Markets Podcast: Open Orphan, Vadim Alexandre on Covid19 Stocks and John Meyer on Resource Stocks

Cathal Friel, Executive Chairman of Open Orphan (ORPH) FOLLOW discusses their full year results for 2019 and outlines what has been achieved in the 6 months since and what they're hoping to achieve in the next six.

Open Orphan is a rapidly growing niche CRO pharmaceutical services group which is a world leader in the testing of vaccines and antivirals through the use of human challenge clinical trials. Conducted from Europe's only 24-bedroom quarantine clinic with onsite virology providing individually isolated rooms and connected to our specialist laboratory facility. Which offers highly specialised virology and immunology laboratory services to support pre-clinical and clinical respiratory drug, antiviral, and vaccine discovery and development. Reliable laboratory analysis underpinned by scientific expertise is essential when processing and analysing clinical samples. Robust quality processes support our team of scientists in the delivery of submission ready data.

Vadim Alexandre, Head of Healthcare at SP Angel discusses the state of play for the coronavirus and how the changing story is likely to affect Covid19 stocks. Companies briefly mentioned include:



(Interview starts at 13 minutes 58 seconds)

John Meyer, Mining analyst and partner at SP Angel talks about gold rising:

Bushveld Minerals (BMN) FOLLOW

Strategic Minerals (SML) FOLLOW

Sunrise Resources (SRES) FOLLOW

Amur Minerals (AMC) FOLLOW

(Interview starts at 28 minutes 37 seconds)    

Disclaimer & Declaration of Interest

The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.

Login or register to post comments

Recent Articles